The University of Buffalo has signed an agreement with Sleep Solutions, Inc., the medical device and health-care services company providing direct-to-patient testing services, to commercialize and distribute an innovative diagnostic testing technology for obstructive sleep apnea (OSA) and Cheyne-Stokes respiration (CSR).
The UB technology is a software algorithm that uses a form of artificial intelligence, a "neural network," to detect obstructive sleep apnea and Cheyne-Stokes respiration using a pulse oximetry signal. The technology is based on analysis of the oximetric recordings of 213 sleep studies. The software has demonstrated very high sensitivities and specificities for diagnosing CSR and OSA.
"This technology represents a substantive advancement in the way OSA can be diagnosed," Michael J. Thomas, president and CEO of Sleep Solutions, Inc. (SSI) said adding, "This new product will broaden our portfolio of services of less expensive, more-patient-friendly diagnostic testing products delivered directly to OSA patients in their homes."
"SSI has contracted with many of the leading managed care organizations throughout the US and developed strong brand awareness of innovation, cost-effectiveness and high-quality services with our core product, NovaSom, QSG," noted Thomas.
Robert J. Genco, UB interim vice president for research and director of the UB Office of Science, Technology Transfer and Economic Outreach (STOR), said there is "a growing worldwide clinical need to provide a cost effective solution for diagnosis of obstructive sleep apnea and Cheyne-Stokes respiration. We are very confident that Sleep Solutions will be able to bring this novel technology to the marketplace resulting in a lower-costing, easier-to-implement diagnostic tool for the public good."
"Sleep Solutions' goal is to develop and market this innovative technology for the diagnosis of OSA directly to third-party payors and physicians," said Thomas.
UB's STOR filed for patent protection on behalf of the Research Foundation of the State University of New York. The technology has been issued two patents and an additional patent application is pending.
The Maryland-based Sleep Solutions provides technology and services for at-home diagnosis, therapy and care management of sleep-disordered breathing, particularly obstructive sleep apnea.
OSA affects 18 million people in the US, with as many as 90 percent going undiagnosed. In addition, CSR, a sleep-disordered breathing condition occurring in patients with congestive heart failure, affects an additional 4.6 million Americans.